Non-small-Cell Lung Carcinoma Clinical Trial
Official title:
A Phase II Study of Cisplatin Plus Docetaxel as Neoadjuvant Therapy for Stages IB Through Selected IIIA NSCLC
The primary objective of this study is to assess the response rate of treatment with two cycles of cisplatin and docetaxel chemotherapy prior to surgery (neoadjuvant) for early stage non-small cell lung cancer (NSCLC). Secondary objectives of this study include assessment of radiographic response rate by computed tomography (CT) scanning, overall survival, time to progression, rate of complete surgical removal, and adverse reactions. In addition, this study will test whether positron emission tomography (PET) imaging can predict a tumor response. Patients who have a response to chemotherapy may receive 2 additional cycles after recovering from surgery.
Non-small cell lung cancer (NSCLC) accounts for 80% of new lung cancer diagnoses in the US.
Surgery is the primary most successful treatment for early stage patients. However, even
lung cancers caught at an early stage (stage IB through selected IIIA) have 5 year survivals
after surgery at a rate of only 10-60%. Postoperative platinum based chemotherapy offers a
4-15% survival benefit, depending on stage in fit patients after complete surgical removal
of early stage disease. Preoperative platinum based chemotherapy has been shown in small
randomized trials to benefit patients with stage IIIA, N2 positive disease, but is not
standard of care in earlier stage disease, such as the population in this study.
The combination of cisplatin and docetaxel is approved in the US for front line therapy of
stage IV NSCLC based on randomized clinical data showing efficacy and manageable toxicity.
Given the efficacy and tolerance of this combination in the metastatic setting, this regimen
is an obvious choice for study in the neoadjuvant setting.
PET imaging is approved in the US for determining size, site and spread of lung cancer
(staging) and has been shown to reduce unnecessary surgery when used as part of preoperative
evaluation. Because NSCLC is not 100% responsive to chemotherapy and CT scans may not show a
change in tumor size until after several cycles of chemotherapy, PET imaging might be an
effective way to provide an earlier and more reliable estimate of response.
Preoperative chemotherapy will be given for a total of two cycles 21 days apart if any
adverse events have resolved and there is no evidence of disease progression. Patients will
undergo CT chest through liver and PET scans for restaging following the second cycle and
will then be scheduled for surgery 3-6 weeks after the second cycle of chemotherapy.
Patients who have responded according to CT and/or PET imaging, or surgical pathology will
go on to receive an additional two cycles of chemotherapy with docetaxel and cisplatin once
the patient has recovered from surgery.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00985855 -
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01048645 -
Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00098085 -
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04995523 -
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
|
Phase 1/Phase 2 | |
Completed |
NCT00910676 -
Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
|
Phase 2 | |
Withdrawn |
NCT00108186 -
Celecoxib Treatment for Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05037825 -
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
|
||
Recruiting |
NCT00379717 -
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Completed |
NCT00404924 -
ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures
|
Phase 3 | |
Completed |
NCT00102505 -
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT02905591 -
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
|
Phase 2 | |
Active, not recruiting |
NCT03088540 -
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
Terminated |
NCT00271323 -
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
|
Phase 2 | |
Completed |
NCT00037817 -
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
|
Phase 1 | |
Completed |
NCT03444766 -
Study of Nivolumab for Advanced Cancers in India
|
Phase 4 | |
Completed |
NCT04351334 -
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
|
||
Active, not recruiting |
NCT02416739 -
Anticancer Activity of Nicotinamide on Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00444015 -
Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Completed |
NCT00105092 -
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
|
Phase 2 |